Patents Assigned to Alexis Biotech Limited
  • Patent number: 7521197
    Abstract: The invention relates to the method for producing antipeptide cytotoxic T lymphocytes (CTLs) by attaching a complex of a class I HLA and a peptide to antigen presenting cell(s) (APCs) present in a sample of peripheral blood lymphocytes (PBLs), optionally removing excess class I HLA/peptide complex, and incubating with proliferative cytokine. The invention further relates to a CTL obtainable by these methods and to a method of treating a subject by administering such a CTL to the subject.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: April 21, 2009
    Assignee: Alexis Biotech Limited
    Inventor: Philip Michael Savage
  • Patent number: 7268219
    Abstract: A complex comprising an HLA Class 1 molecule and attaching means for selectively attaching the HLA class 1 molecule to a target cell is disclosed, and a method is provided for producing or enhancing an immunological response against a target cell, by attaching said complex to the target cell. Where the target is a diseased, foreign or malignant cell, this method may be used to promote the lysis of the targeted cell by T cells in the immune system. Where the target cell is an antigen presenting cell, this method may be used to promote the proliferation of specific T cell clones. The invention is of potential use in the prevention and treatment of malignant diseases including cancer and leukemia, infectious diseases including viral infections such as HIV, bacterial infections including tuberculosis, and parasitic infections including malaria.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 11, 2007
    Assignee: Alexis Biotech Limited
    Inventor: Philip Michael Savage
  • Patent number: 7264965
    Abstract: A complex including an HLA class I molecule and attaching means for selectively attaching the HLA class I molecule to a target is disclosed, and a method is provided for producing or enhancing an immunological response against a target cell, by attaching said complex to the target cell. Where the target cell is diseased, foreign, or malignant cell, this method may be used to promote lysis of the target cell by T cells in the immune system. Where the target cell is an antigen presenting cell, this method may be used to promote proliferation of specific T cell clones. Uses include prevention and treatment of diseases including cancer, leukaemia, infectious diseases, viral infections, such as HIV, bacterial infections, such as tuberculosis, and parasitic infections such as malaria.
    Type: Grant
    Filed: April 5, 2002
    Date of Patent: September 4, 2007
    Assignee: Alexis Biotech Limited
    Inventor: Philip Michael Savage